Centessa Pharmaceuticals News and Activities
Presence
Headquarters: United States (USA)
Acquisition, funding and merger involving Centessa Pharmaceuticals.
- Eli Lilly has announced the acquisition of Centessa Pharmaceuticals (posted on March 31 2026).
Executives
View the org chart displaying its 34 main executives
Most searched biographies at Centessa Pharmaceuticals
- Mario Alberto Accardi, Chief Executive Officer
- Francesco De Rubertis, Chairman of The Board
- Mary Lynne Hedley, Director
Popular executive movements at Centessa Pharmaceuticals
- Saurabh Saha, Chief Executive Officer and Director, will leave the company on Jan. 1, 2026 (posted on December 11 2025).
- Mario Accardi who is President of Orexin Program, will be promoted to Chief Executive Officer on Jan. 1, 2026 (posted on December 11 2025).
Create your alert
to follow the executive moves at Centessa Pharmaceuticals.
Pharmaceuticals
Centessa Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Centessa Pharmaceuticals
- Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors | Centessa Pharmaceuticals
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise | Centessa Pharmaceuticals
- Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day | Centessa Pharmaceuticals
- View more press releases Close
Social media about Centessa Pharmaceuticals
- Centessa Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Centessa Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
